Introduction Dacomitinib and gefitinib are irreversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKI) indicated for the first-line treatment of patients with …

Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …

Objectives To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy
for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing …

Purpose Concurrent proton pump inhibitor (PPI) use might reduce the plasma concentration
of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the …

Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor indicated for the treatment of patients with advanced non-small-cell lung cancer …

Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse
event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall …

Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …

Abstract Background and Objective Dacomitinib is a kinase inhibitor indicated for the first-
line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal …

In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …

Background Dacomitinib is a second-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI). ARCHER-1050 showed that this agent can …